The long-term effect of Helicobacter pylori eradication on COX-1/2, 5-LOX and leukotriene receptors in patients with a risk gastritis phenotype--a link to gastric carcinogenesis.
To identify the role of eicosanoid-mediated pathways for gastric carcinogenesis, the expression of enzymes (COX-1, COX-2, 5-LOX) and receptors (BLT-1, CysLTR(1)) were immunohistochemically studied in H. pylori positive patients with a risk gastritis phenotype and either successful or unsuccessful eradication (n=12, each; followed up for a median of 5 years). Gastric cancer risk index improved significantly after successful eradication (p<0.001). Semiquantitative immunohistochemistry revealed distinct significant changes in the expression patterns for COX-2, CysLTR1, COX-1 and BLT-1 depending on the eradication outcome, whereas 5-LOX expression was not altered. These results suggest an involvement of the COX-LOX pathway in gastric carcinogenesis.
Venerito
Marino
M
Department of Gastroenterology, Hepatology, Infectious Diseases, Otto-von-Guericke University Hospital, Leipziger Str. 44, D-39120 Magdeburg, Germany.
Kuester
Doerthe
D
Wex
Thomas
T
Roessner
Albert
A
Malfertheiner
Peter
P
Treiber
Gerhard
G
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism*; D002471:Cell Transformation, Neoplastic / Q000378:metabolism; D051545:Cyclooxygenase 1 / Q000378:metabolism*; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D005753:Gastric Mucosa / Q000187:drug effects / Q000201:enzymology / Q000382:microbiology; D005756:Gastritis / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000382:microbiology; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011446:Prospective Studies; D018077:Receptors, Leukotriene / Q000378:metabolism*; D018102:Receptors, Leukotriene B4 / Q000378:metabolism; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D013274:Stomach Neoplasms / Q000201:enzymology / Q000382:microbiology / Q000517:prevention & control*; D013997:Time Factors; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; C513240:LTB4R protein, human; D018077:Receptors, Leukotriene; D018102:Receptors, Leukotriene B4; D001094:Arachidonate 5-Lipoxygenase; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; C083169:leukotriene D4 receptor